Evidence map›Paper›PMID 34185055›Full record

ArticleTranslational vision science & technology2021

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration.

Maximilian Pfau, Soumya Sahu, Rawan Allozi Rupnow, Kathleen Romond, Desiree Millet, Frank G Holz, Steffen Schmitz-Valckenberg, Monika Fleckenstein, Jennifer I Lim, Luis de Sisternes and 3 more

Open access · goldAbstract read
In one paragraph

Article in Translational vision science & technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Deep learning in optical coherence tomography: Where are the gaps?Clinical & experimental ophthalmology · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Maximilian PfauDepartment of Biomedical Data Science, Stanford University, Palo Alto, CA, USA.
Soumya SahuDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Rawan Allozi RupnowDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Kathleen RomondDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Desiree MilletDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Frank G HolzDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Steffen Schmitz-ValckenbergDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Monika FleckensteinJohn A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.
Jennifer I LimDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Luis de SisternesCarl Zeiss Meditec AG, Dublin, CA, USA.
Theodore LengByers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA.
Daniel L RubinDepartment of Biomedical Data Science, Stanford University, Palo Alto, CA, USA.
Joelle A HallakDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
University of Illinois Chicago · USStanford University · USUniversity of Bonn · DECarl Zeiss (United States) · USUniversity of Utah · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AAKALU, VINAY · 1985 to 2025
$14.8M
Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY001792NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

Purpose: To probabilistically forecast needed anti-vascular endothelial growth factor (anti-VEGF) treatment frequency using volumetric spectral domain-optical coherence tomography (SD-OCT) biomarkers in neovascular age-related macular degeneration from real-world settings. Methods: SD-OCT volume scans were segmented with a custom deep-learning-based analysis pipeline. Retinal thickness and reflectivity values were extracted for the central and the four inner Early Treatment Diabetic Retinopathy Study (ETDRS) subfields for six retinal layers (inner retina, outer nuclear layer, inner segments [IS], outer segments [OS], retinal pigment epithelium-drusen complex [RPEDC] and the choroid). Machine-learning models were probed to predict the anti-VEGF treatment frequency within the next 12 months. Probabilistic forecasting was performed using natural gradient boosting (NGBoost), which outputs a full probability distribution. The mean absolute error (MAE) between the predicted versus actual anti-VEGF treatment frequency was the primary outcome measure. Results: In a total of 138 visits of 99 eyes with neovascular AMD (96 patients) from two clinical centers, the prediction of future anti-VEGF treatment frequency was observed with an accuracy (MAE [95% confidence interval]) of 2.60 injections/year [2.25-2.96] (R2 = 0.390) using random forest regression and 2.66 injections/year [2.31-3.01] (R2 = 0.094) using NGBoost, respectively. Prediction intervals were well calibrated and reflected the true uncertainty of NGBoost-based predictions. Standard deviation of RPEDC-thickness in the central ETDRS-subfield constituted an important predictor across models. Conclusions: The proposed, fully automated pipeline enables probabilistic forecasting of future anti-VEGF treatment frequency in real-world settings. Translational Relevance: Prediction of a probability distribution allows the physician to inspect the underlying uncertainty. Predictive uncertainty estimates are essential to highlight cases where human-inspection and/or reversion to a fallback alternative is warranted.

Indexed as

Angiogenesis InhibitorsWet Macular DegenerationBevacizumabHumansVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsBevacizumabVascular Endothelial Growth Factor A

Identifiers

PMID34185055
PMCPMC8254013
OpenAlexW3175965640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.